About three years ago, John Monroe over at Elite Opportunity Pro suggested a stock to his clients, BioTelemetry, Inc. (NASDAQ: BEAT), a NASDAQ small cap that provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. At the time, the stock was around the $8 and change level, but has since traded north of $33 per share - which is even sharply up from its April low of $25 per share. The lesson all along though when it came to investing in BEAT was to buy it when it was down, have a little patience, and hope management did the right things. It now goes without saying they've done that in spades. A similar small cap we first brought to your attention here in the free newsletter back in July of last year Biotricity Inc. (OTCQB: BTCY), continues to make some waves in the same space as BioTelemetry, Inc. (BEAT). However, with BEAT sporting a market cap of over $900M now, BTCY sports a market cap of just $73M - suggesting a tremendous growth opportunity if BTCY management can even do remotely close to what BEAT's management has done over the last few years. It's not as if BTCY is in the wrong space either. With baby boomers aging and remote medical monitoring becoming more and more prevalent, the company's Bioflux1 solution appears to offer tremendous promise - an advanced remote cardiac monitoring technology engineered to assist diagnoses of heart conditions, while at the same time enhancing patient outcomes, augmenting revenue capture for medical practices, and curbing healthcare costs. Bioflux is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information back to the physician or practice. Together with their proprietary software, highly customizable reports, and 24/7 monitoring centre, the Bioflux system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians' existing platforms and workflows. If that isn't enough, Biotricity has taken its expertise and has applied it to the wearable space with its in development Biolife - a personal heart monitor for consumers at risk of cardiovascular disease (CVD). Biolife is aimed at providing individuals with heart conditions with clinical-grade information of their heart's performance of the same standard their doctors use. In addition to ECG data, Biolife will also give patients information on their respiration, physical activity, calorie burn, core body temperature, and more-all presented in an easy-to-understand manner. Managing a long-term chronic illness can be difficult, but it appears Biolife isn't far from helping those individuals realize a better life. Its evidence-based feedback on someone's progress will assist in forming healthy lifestyle habits and help motivate folks to stick with medication and other treatment requirements. Used in a manner consistent with a doctor's instructions, Biolife will help guide someone's efforts to manage their heart condition and improve quality of life. It will also likely be of great help to people at risk of CVD because of family history, obesity, diabetes or stress, by providing an evidence-based foundation for preventative care. Although still in development, it is anticipated Biolife will be available to consumers in the near future. It's clearly an exciting speculative play with some significant potential. Although the company is still in the development stage, any sort of serious traction on the revenue front could end providing investors with some real returns. Both the medical monitoring and the wearable space have room for heck of a lot more technology and players. Wearables, as it stands right now, has been projected to grow from $14B in 2016 to over $34B by 2020, and the number of connected wearable devices expected to grow is mind boggling. There's clearly a lot going on in the world of technology right now with the Internet of Things (IoT), robotics, eSports and the cloud among those leading the charge. Maybe that's why the NASDAQ and specifically tech has continued to lead these markets higher and higher of the last several years. It's really not a matter of opportunities, as much as it is just finding the right ones in the right space at the right time. Maybe Biotricity Inc. (OTCQB: BTCY) will end up being one of what will probably end up being 100's of winners over the next few years.